NCT02174588

Brief Summary

Since introduction in 1989, propofol has gained wide acceptance for sedation during endoscopic procedures. The optimal sedation drug during esophagogastroendoscopy (EGD) is not established. Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol. In this study, the investigators want to compare the patient satisfaction with EGD following balanced propofol sedation (BPS) versus propofol sedation alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
22

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2013

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 7, 2013

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

June 23, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 25, 2014

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 4, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 4, 2015

Completed
Last Updated

January 25, 2017

Status Verified

January 1, 2017

Enrollment Period

2.1 years

First QC Date

June 23, 2014

Last Update Submit

January 23, 2017

Conditions

Keywords

sedation, propofol, midazolam

Outcome Measures

Primary Outcomes (1)

  • visual analog scale

    The patient satisfaction with EGD following balanced propofol sedation (BPS) versus propofol sedation alone

    Within the 24 hours after EGD

Secondary Outcomes (1)

  • complications rates

    Within the 1 hour after EGD

Other Outcomes (3)

  • complications rates

    Within the 1 hour after EGD

  • total dose of the sedation drugs

    Within the 1 hour after EGD

  • visual analog scale

    Within the 1 hour after EGD

Study Arms (2)

balanced propofol group

EXPERIMENTAL
Drug: Midazolam + propofol

propofol alone group

ACTIVE COMPARATOR
Drug: propofol

Interventions

Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.

balanced propofol group

propofol are used for sedation drug

propofol alone group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • over 19 years old, male and female
  • patients who have plan to get esophagogastroduodenoscopy (EGD)

You may not qualify if:

  • ASA class III or IV
  • Allergies to propofol, sulfites or eggs
  • patients who had surgery for esophagus, stomach or duodenum
  • inpatients
  • patients who had sleep apnea, gastroparesis or achalasia
  • patients who are taking sedative drugs more than 6 months
  • pregnancy
  • hypotension (systolic pressure less than 90mmHg), bradycardia (pulse rates less than 50 times per minute) or hypoxia (SpO2 less than 90%)
  • psychiatric or neurologic problems (ex. epilepsy or dementia)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yonsei university College of Medicine

Seoul, Seoul, 120-752, South Korea

Location

MeSH Terms

Interventions

MidazolamPropofol

Intervention Hierarchy (Ancestors)

BenzodiazepinesBenzazepinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2014

First Posted

June 25, 2014

Study Start

January 7, 2013

Primary Completion

February 4, 2015

Study Completion

February 4, 2015

Last Updated

January 25, 2017

Record last verified: 2017-01

Locations